Polypeptide methionine site thioimine modification method and application thereof

By using ruthenium complex catalyzed sulfimine modification method in air atmosphere, the problem of insufficient modification of the methionine site polypeptide is solved, and the precise modification of the methionine site of the polypeptide and cyclic peptide synthesis are achieved. It is suitable for The preparation of polypeptide drugs provides inexpensive, mild reaction conditions and the applicability of complex substrates.

CN118978566APending Publication Date: 2024-11-19LANZHOU UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411060975.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-05
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

In the prior art, the precise modification methods of polypeptides at methionine sites are insufficient, and cannot meet the needs of rapid development of polypeptide drugs. There is a lack of new types of precise modification reactions based on methionine.

Method used

Using a polypeptide containing methionine and N-acyloxyamide as raw materials in an air atmosphere, using a ruthenium complex as a catalyst, reacting in the presence of silver acetate and ligand to achieve the methionine position of the polypeptide The sulfimine polypeptide was modified by solid phase reaction and liquid chromatography to obtain the sulfimine polypeptide.

Benefits of technology

It realizes the precise modification of the methionine site of the polypeptide, the raw materials are cheap, the reaction conditions are mild, and it is suitable for complex substrates. It provides a new method for cyclic peptide synthesis and can intelligently respond to reducing substances such as glutathione. Achieve traceless release of the peptide.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004977838670000021
    Figure BDA0004977838670000021
  • Figure BDA0004977838670000031
    Figure BDA0004977838670000031
  • Figure BDA0004977838670000041
    Figure BDA0004977838670000041
Patent Text Reader

Abstract

The invention discloses a method for modifying a methionine site of a polypeptide with thioimine and application of the method. The method comprises the following steps: in an air atmosphere, taking polypeptide containing methionine and N-acyloxy amide as raw materials, taking a ruthenium complex as a catalyst, reacting in a solvent in the presence of a ligand and silver acetate, and after the reaction is finished, separating and purifying to obtain a corresponding thioimine modified polypeptide product. The raw materials are simple to synthesize, the operation is simple and convenient, the reaction condition is mild, the reaction efficiency is high, the substrate application range is wide, complex substrates including exenatide, aviptadil, tecopeptide, artesunate, 5-carboxyl fluorescein and the like are included, and the method is suitable for intramolecular cyclic peptide synthesis, compatible liquid phase synthesis and solid phase synthesis. Besides, an N = S bond of the obtained product can be reduced by glutathione and other reducing substances to obtain corresponding polypeptide and amide, intelligent response release of the polypeptide can be achieved, and a new thought is provided for preparation of polypeptide drugs and coupling drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biochemical technology, and specifically relates to a method for modifying the methionine site of a polypeptide with sulfilimine. The present invention also relates to the application of the sulfilimine polypeptide prepared by the method in the preparation of polypeptide drugs. Background Art

[0002] Many active substances in the human body exist in the form of peptides. Peptides play an important role in regulating the functional activities of various systems, organs, tissues and cells of the body and in life activities, and are often used in functional analysis, antibody research, drug development and other fields. With the increasing demand for peptide drugs, more and more post-synthetic modifications and orthogonal reactions have been developed and applied to peptides (Biochemistry, 2017, 56, 3863-3873). Cysteine ​​and methionine are the only two sulfur-containing protein amino acids. The modification methods of cysteine ​​have made great progress and application. In comparison, the modification methods of methionine have only been reported sporadically (Biochemistry 2020, 59, 132-138). Timothy J. Deming et al. disclosed (Chem. Commun. 2013, 49, 5144-5146) a method for selectively modifying polypeptide methionine residues with alkyl halides under acidic conditions to obtain corresponding sulfonium salts; Xiong Xiaofeng et al. (Org. Lett. 2021, 23, 8543-8548) heated the above-mentioned sulfonium salts to remove methyl halides, thereby achieving alkylation modification of methionine; Christopher J. Chang and F. Dean Toste et al. (Science 2017, 355, 597-602) disclosed a strategy for oxidative modification of methionine residues using oxaziridine reagents, achieving rapid and highly chemically selective polypeptide and protein sulfonimide modification and bioorthogonal coupling on polypeptides and proteins; Matthew J. Gaunt et al. (Nature 2018, 562, 563–568) disclosed a high-valent iodine reagent for selectively modifying methionine, which can achieve rapid functionalization of proteins and polypeptides; David WC MacMillan et al. (J. Am. Chem. Soc. 2020, 142, 21260-21266) disclosed a method for achieving precise derivatization of methyl groups on methionine side chains through photoredox catalysis. Although the above progress has been made in the precise modification of peptides based on methionine sites, it is far from meeting the needs of rapid development of peptides. New types of precise modification reactions of peptides based on methionine are urgently needed to promote the development of peptide drugs. Summary of the invention

[0003] Based on the above, the purpose of the present invention is to provide a method for precise modification of sulfilimine at the methionine site of a polypeptide, and apply it to the synthesis of cyclic peptides.

[0004] Another object of the present invention is to provide a sulfilimine polypeptide prepared by the above method.

[0005] Another object of the present invention is to provide the use of the sulfilimine polypeptide prepared by the above method in the preparation of polypeptide drugs.

[0006] To achieve its purpose, the present invention adopts the following technical solution:

[0007] A method for modifying the methionine site of a polypeptide with sulfilimine, specifically comprising: reacting in an air atmosphere with a polypeptide containing methionine and an N-acyloxyamide as raw materials, with a ruthenium complex as a catalyst, in the presence of silver acetate and a ligand in a solvent, and separating and purifying after the reaction to obtain a sulfilimine-modified polypeptide compound, wherein the reaction formula is as follows:

[0008]

[0009] In the above reaction formula, the polypeptide component 1 is a polypeptide containing methionine, the sequence length of the polypeptide is 1-39 amino acids, and can be connected to a solid phase resin for reaction; in the N-acyloxyamide component 2, R 1 is a C1-C18 alkyl, phenyl or 5-carboxyfluorescein substituted phenyl, R 2 Any one of acetyl, valeryl, benzoyl and 2-chloroacetyl; the ruthenium complex is any one of tris(triphenylphosphine)ruthenium dichloride, benzalbis(tricyclohexylphosphine)ruthenium dichloride or tris(1,10-phenanthroline)ruthenium dichloride.

[0010] As a further preferred embodiment of the technical solution of the present invention, the solid phase reaction process is:

[0011] The peptide component 1 containing methionine was synthesized on the solid phase resin, and then N-acyloxyamide component 2 (5 equivalents), AgOAc (10 μmol / mL) and DCE (9 mL) were added in sequence, and finally a premix of a methanol solution (1 mL) of a ruthenium complex (0.1 equivalents) and a ligand (0.2 equivalents) was added, and the peptide synthesis filter syringe was placed on an oscillator for 30 minutes (one round of reaction), and the premixed methanol mixed solution (1 mL) was added again, and the reaction was shaken for 30 minutes. After a total reaction of 2 hours (four rounds of reaction), the product was cleaved from the resin and purified by semi-preparative high performance liquid chromatography to obtain a purified product.

[0012] Furthermore, the molar ratio of the polypeptide component 1, the N-acyloxyamide component 2, the ruthenium complex, and the ligand is 1:(1-10):(0.05-0.1):(0.1-0.2), and the amount of silver acetate is 1-50 μmol / mL reaction solvent.

[0013] Furthermore, the ruthenium complex is any one of tris(triphenylphosphine)ruthenium dichloride, benzalbis(tricyclohexylphosphine)ruthenium dichloride or tris(1,10-phenanthroline)ruthenium dichloride, preferably tris(triphenylphosphine)ruthenium dichloride.

[0014] Furthermore, the ligand is any one of benzohydroxamic acid, benzamide or benzoic acid, preferably benzohydroxamic acid.

[0015] Furthermore, the solvent is an organic solvent or a mixed solution of an organic solvent and water, preferably any one of methanol, ethanol, acetonitrile, N,N-dimethylformamide, dichloromethane, ethyl acetate, toluene, chloroform, ether, acetone, tetrahydrofuran, 1,4-dioxane or a mixed solution of methanol and water, more preferably methanol.

[0016] Furthermore, the reaction temperature is 0-60°C. Too high a temperature may destroy the polypeptide structure.

[0017] In the above method for modifying the methionine site of a polypeptide with sulfilimine, when the polypeptide component 1 and the N-acyloxyamide component 2 are the same substance, the sulfilimine polypeptide 3 is a cyclic peptide.

[0018] The sulfilimine polypeptide can be prepared by the above method. Since the sulfilimine polypeptide can undergo N=S bond reduction under the reduction of glutathione, cysteine ​​or dithiothreitol to achieve polypeptide release, the sulfilimine polypeptide is expected to be used for the preparation of polypeptide drugs.

[0019] The beneficial effects of the present invention are:

[0020] 1. The method for modifying the polypeptide methionine site with sulfilimine of the present invention has cheap raw materials, simple synthesis, mild reaction conditions, no need for inert gas protection, simple operation, and good amino acid reaction site selectivity.

[0021] 2. The substrate of the present invention has a wide range of applications, including complex substrates such as exenatide, actipidil, teicoplanin, artesunate, 5-carboxyfluorescein, etc., and is compatible with liquid phase reactions and solid phase synthesis.

[0022] 3. The present invention provides a new method for synthesizing cyclic peptides.

[0023] 4. The product obtained by the present invention can intelligently respond to reducing substances such as glutathione to achieve traceless release of polypeptides. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 This is the HPLC chromatogram of the reaction system of Example 56;

[0025] Figure 2 HPLC chromatogram of retention time of compound 3t;

[0026] Figure 3 This is the HPLC chromatogram of the reaction system of Example 57;

[0027] Figure 4 The retention time HPLC chromatogram of compound 3ad. DETAILED DESCRIPTION

[0028] The present invention is described in detail below in conjunction with specific embodiments, but these specific embodiments do not constitute any form of limitation to the actual protection scope of the present invention.

[0029] Example 1

[0030]

[0031] Boc-L-methionine methyl ester 1a (0.10 mmol), N-acetoxybenzamide 2a (0.12 mmol), tris(triphenylphosphine)ruthenium dichloride (0.005 mmol), benzohydroxamic acid (0.01 mmol), silver acetate (0.02 mmol) were added to a clean 10 mL reaction tube, and the solvent was 2 mL of methanol. The reaction was stirred at 37° C. for 30 minutes under air atmosphere, and then concentrated and column chromatographed (DCM / MeOH=40 / 1) to obtain product 3a as a white solid with a yield of 96%. The mass spectrum data of the product are as follows, and the nuclear magnetic resonance data are shown in Table 2.

[0032] HRMS(ESI)C 18 H 26 N 2 NaO 5 S[M+Na] + Calcd:405.1455,Found:405.1458.

[0033] Example 2

[0034] The same as Example 1, except that the polypeptide component 1 is Boc-L-methionine-glycine benzyl ester, the product 3b is obtained as a white solid with a yield of 95%. The structural formula and mass spectrum data of the product are as follows, and the nuclear magnetic resonance data are shown in Table 2.

[0035]

[0036] HRMS(ESI)C 26 H34 N 3 O 6 S[M+H] + Calcd:516.2163,Found:516.2172.

[0037] Example 3

[0038] The same as Example 1, except that the polypeptide component 1 is Fmoc-glycine-L-methionine methyl ester, the reaction is carried out for 1 hour to obtain product 3c as a white solid with a yield of 94%. The structural formula and mass spectrum data of the product are as follows, and the nuclear magnetic resonance data are shown in Table 2.

[0039]

[0040] HRMS(ESI)C 30 H 31 N 3 NaO 6 S[M+Na] + Calcd:584.1826,Found:584.1825.

[0041] Example 4

[0042] The same as Example 3, except that the polypeptide component 1 is Fmoc-O-tert-butyl-L-glutamic acid-L-methionine methyl ester, the product 3d is obtained as a white solid with a yield of 94%. The structural formula and mass spectrum data of the product are as follows, and the nuclear magnetic resonance data are shown in Table 2.

[0043]

[0044] HRMS(ESI)C 37 H 44 N 3 O 8 S[M+H] + Calcd:690.2844,Found:690.2843.

[0045] Example 5

[0046] The same as Example 1, except that the polypeptide component 1 is Fmoc-O-tert-butyl-L-serine-L-methionine methyl ester, the product 3e is obtained as a white solid with a yield of 95%. The structural formula and mass spectrum data of the product are as follows, and the nuclear magnetic resonance data are shown in Table 2.

[0047]

[0048] HRMS(ESI)C 35 H 42 N 3 O7 S[M+H] + Calcd:648.2738,Found:648.2754.

[0049] Example 6

[0050] The same as Example 1, except that the polypeptide component 1 is Fmoc-S-trityl-L-cysteine-L-methionine methyl ester, the reaction is carried out for 3 hours to obtain the product 3f as a white solid with a yield of 84%. The structural formula and mass spectrum data of the product are as follows, and the nuclear magnetic resonance data are shown in Table 2.

[0051]

[0052] HRMS(ESI)C 50 H 48 N 3 O 6 S 2 [M+H] + Calcd:850.2979,Found:850.2977.

[0053] Example 7

[0054] The same as Example 1, except that the polypeptide component 1 is Fmoc-O-tert-butyl-L-tyrosine-L-methionine methyl ester, 3 g of product was obtained as a white solid with a yield of 98%. The structural formula and mass spectrum data of the product are as follows, and the nuclear magnetic resonance data are shown in Table 2.

[0055]

[0056] HRMS(ESI)C 41 H 46 N 3 O 7 S[M+H] + Calcd:724.3051,Found:724.3065.

[0057] Example 8

[0058] The same as Example 1, except that the polypeptide component 1 is Fmoc-N-Boc-L-tryptophan-L-methionine methyl ester, the product 3h is obtained as a white solid with a yield of 95%. The structural formula and mass spectrum data of the product are as follows, and the nuclear magnetic resonance data are shown in Table 2.

[0059]

[0060] HRMS(ESI)C 44 H 47 N 4 O8 S[M+H] + Calcd:791.3109,Found:791.3106.

[0061] Example 9

[0062] The same as Example 1, except that polypeptide component 1 is Boc-L-methionine-glycine benzyl ester, component 2 is N-acetoxybutyramide, and the reaction is performed for 1 hour to obtain product 3i as a white solid with a yield of 96%. The structural formula and mass spectrum data of the product are as follows, and the nuclear magnetic resonance data are shown in Table 2.

[0063]

[0064] HRMS(ESI)C 23 H 36 N 3 O 6 S[M+H] + Calcd:482.2319,Found:482.2320.

[0065] Example 10

[0066] The reaction was similar to Example 9, except that component 2 was N-acetoxyhexanamide. The reaction lasted for 30 minutes to obtain product 3j, which was a white solid with a yield of 96%. The structural formula and mass spectrum data of the product are as follows, and the nuclear magnetic resonance data are shown in Table 2.

[0067]

[0068] HRMS(ESI)C 25 H 40 N 3 O 6 S[M+H] + Calcd:510.2632,Found:510.2635.

[0069] Embodiment 11

[0070] The same as Example 3, except that component 2 is an artesunate derivative After reacting for 30 minutes, the product 3k was obtained as a white solid with a yield of 72%.

[0071] The mass spectrum data of the product are as follows, and the NMR data are shown in Table 2.

[0072]

[0073] HRMS(ESI)C 42 H 54 N 3 O12 S[M+H] + Calcd:824.3423,Found:824.3422.

[0074] Example 12

[0075] The reaction was similar to Example 1, except that the reaction temperature was 25°C and the yield of 3a was 90%.

[0076] Embodiment 13

[0077] The reaction was similar to Example 12, except that component 2 was N-benzoyloxybenzamide, and the yield of 3a was 87%.

[0078] Embodiment 14

[0079] The reaction was similar to Example 12, except that component 2 was N-pivaloyloxybenzamide, and the yield of 3a was 54%.

[0080] Embodiment 15

[0081] The reaction was similar to Example 12, except that component 2 was N-(2-chloroacetoxy)benzamide, and the yield of 3a was 21%.

[0082] Example 16

[0083] The reaction was similar to Example 14 except that benzohydroxamic acid was not added. The reaction was carried out at 25° C. for 12 hours. The yield of 3a was 29%.

[0084] Embodiment 17

[0085] The reaction was similar to Example 16 except that benzamide (0.01 mmol) was added. The yield of 3a was 35%.

[0086] Embodiment 18

[0087] Almost the same as Example 16, except that benzoic acid (0.01 mmol) was added, and the yield of 3a was 31%.

[0088] Embodiment 19

[0089] The reaction was similar to Example 14, except that the catalyst was benzylidenebis(tricyclohexylphosphine)dichlororuthenium. The reaction was carried out at 37°C for 30 minutes, and the yield of 3a was 84%.

[0090] Embodiment 20

[0091] The process is substantially the same as Example 19, except that the catalyst is dichlorotri(1,10-phenanthroline)ruthenium chloride, and the yield of 3a is 17%.

[0092] Examples 21-33

[0093] It is roughly the same as Example 1, the only difference is that the solvent is different, as shown in Table 1:

[0094] Table 1 Data of Examples 21-33 of the present invention

[0095] Example Solvents Yield (%) Example Solvents Yield (%) Embodiment 21 Ethanol 61 Embodiment 28 Chloroform 16 Embodiment 22 Acetonitrile 67 Embodiment 29 Ether 42 Embodiment 23 N,N-Dimethylformamide 18 Embodiment 30 acetone 52 Embodiment 24 Dichloromethane 18 Embodiment 31 Tetrahydrofuran 15 Embodiment 25 1,2-Dichloroethane 56 Embodiment 32 1,4-Dioxane 22 Embodiment 26 Ethyl acetate 53 Embodiment 33 Dimethyl sulfoxide 3 Embodiment 27 Toluene 54 Embodiment 34 Methanol: water = 1:1 56

[0096] Example 35-51 Water-soluble long peptide

[0097] Embodiment 35

[0098] Tris(triphenylphosphine)ruthenium dichloride (2 μmol) and benzohydroxamic acid (4 μmol) were fully shaken in 2 mL of methanol for 5 minutes in advance. Substance P (5 μmol), N-acetoxybutyramide (25 μmol), silver acetate (10 μmol), 1 mL of methanol, and 0.5 mL of the pre-prepared methanol mixed solution were added to a clean 10 mL reaction tube in sequence. After stirring and reacting at 37°C under air atmosphere for 30 minutes (first round of reaction), 0.5 mL of the above methanol mixed solution was added again and reacted again for 30 minutes (second round of reaction). After 2 rounds of reaction (1 hour), the product 31 was purified by semi-preparative liquid chromatography as a white solid with a yield of 60%. The structural formula and mass spectrum of the product are as follows:

[0099]

[0100] HRMS(ESI)C 67 H 106 N 19 O 14 S[M+H] + Calcd:1432.7882,Found:1432.7867.

[0101] Embodiment 36

[0102] In this embodiment, component 2 is N-acetoxyoctanamide, and other parameters and reaction conditions are the same as those in Example 35. The product 3m is isolated as a white solid with a yield of 52%. The structural formula and mass spectrum of the product are as follows:

[0103]

[0104] HRMS(ESI)C 71 H 114 N 19 O 14 S[M+H] + Calcd:1488.8508,Found:1488.8467.

[0105] Embodiment 37

[0106] In this embodiment, component 2 is N-acetoxy stearamide, and other parameters and reaction conditions are the same as those in Example 35. The product 3n is isolated as a white solid with a yield of 29%. The structural formula and mass spectrum of the product are as follows:

[0107]

[0108] HRMS(ESI)C 81 H 134 N 19 O 14 S[M+H] + Calcd:1629.0073,Found:1428.9745.

[0109] Embodiment 38

[0110] In this embodiment, component 2 is N-acetoxy-3-cyclohexylpropionamide, and other parameters and reaction conditions are the same as those in Example 35. The product 3o is isolated as a white solid with a yield of 50%. The structural formula and mass spectrum of the product are as follows:

[0111]

[0112] HRMS(ESI)C 72 H 114 N 19 O 14 S[M+H] + Calcd:1500.8508,Found:1500.8462.

[0113] Embodiment 39

[0114] In this embodiment, component 2 is acetoxy benzyl carbamate, and other parameters and reaction conditions are the same as those in Example 35. The product 3p is isolated as a white solid with a yield of 44%. The structural formula and mass spectrum of the product are as follows:

[0115]

[0116] HRMS(ESI)C 71 H 106 N 19 O 15 S[M+H] + Calcd:1496.7831,Found:1496.7803.

[0117] Embodiment 40

[0118] In this embodiment, component 2 is N-acetoxy-3-[3,4-(methylenedioxy)phenyl]propionamide, and other parameters and reaction conditions are the same as those in Example 35. The product 3q is isolated as a white solid with a yield of 53%. The structural formula and mass spectrum of the product are as follows:

[0119] HRMS(ESI)C 73 H 108 N 19 O 16 S[M+H] + Calcd:1538.7937,Found:1538.7897.

[0120] Embodiment 41

[0121] In this embodiment, component 2 is N-(6-(acetoxyamino)-6-oxohexyl)-7-(diethylamino)-2-oxo-2H-chromene-3-carboxamide, and other parameters and reaction conditions are the same as those in Example 35. The product 3r is isolated as a yellow solid with a yield of 24%. The structural formula and mass spectrum of the product are as follows:

[0122]

[0123] HRMS(ESI)C 83 H 124 N 21 O 17 S[M+H] + Calcd:1718.9199,Found:1718.9166.

[0124] Embodiment 42

[0125] In this embodiment, component 2 is N-acetoxyamide 2i, and other parameters and reaction conditions are the same as those in Example 35. The product 3s is isolated as a white solid with a yield of 34%. The structural formula and mass spectrum of the product are as follows:

[0126]

[0127] HRMS(ESI)C 82 H 126 N 19 O 20 S[M+H] + Calcd:1728.9142,Found:1728.9105.

[0128] Embodiment 43

[0129] In this embodiment, component 2 is L-leucine-L-glutamine (N-acetyloxy)-L-valine-L-tyrosinamide, and other parameters and reaction conditions are the same as those in Example 35. The product 3t is isolated as a white solid with a yield of 62%. The structural formula and mass spectrum of the product are as follows:

[0130]

[0131] HRMS(ESI)C 94 H 150 N 26 O 20 S[M+2H] 2 +Calcd:998.0632,Found:998.0422.

[0132] Embodiment 44

[0133] Tris(triphenylphosphine)ruthenium dichloride (2μmol) and benzohydroxamic acid (4μmol) were shaken in 2mL methanol for 5 minutes in advance. Systemine (3μmol), N-acetoxy-3-cyclohexylpropionamide (30μmol), silver acetate (20μmol), 2mL methanol, and 0.3mL of the above pre-prepared methanol mixed solution were added to a clean 10mL reaction tube in sequence. After stirring at 37°C in an air atmosphere for minutes (the first round of reaction), 0.3mL of the above methanol mixed solution was added again and reacted again for 30 minutes (the second round of reaction). After 4 rounds of reaction (2 hours), the product 3u was purified by semi-preparative liquid chromatography as a white solid with a yield of 17%. The structural formula and mass spectrum of the product are as follows:

[0134]

[0135] HRMS(ESI)C 94 H 161 N 27 O 29 S[M+2H] 2 +Calcd:1082.5849,Found:1082.5820.

[0136] Embodiment 45

[0137] In this example, the polypeptide component 1 is teicoplanin, and the other parameters and reaction conditions are the same as those in Example 44. The product 3v is isolated as a white solid with a yield of 43%. The structural formula and mass spectrum of the product are as follows:

[0138]

[0139] HRMS(ESI)C 145 H 227 N 41 O32 S[M+2H] 2+ Calcd:1543.8570,Found:1543.8521.

[0140] Embodiment 46

[0141] In this embodiment, component 2 is N-acetoxyoctanamide, and other parameters and reaction conditions are the same as those in Example 45. The product 3w is isolated as a white solid with a yield of 55%. The structural formula and mass spectrum of the product are as follows:

[0142]

[0143] HRMS(ESI)C 144 H 227 N 41 O 32 S[M+2H] 2+ Calcd:1537.8570,Found:1537.8540.

[0144] Embodiment 47

[0145] In this embodiment, polypeptide component 1 is Atridil, component 2 is N-acetoxybenzamide, and other parameters and reaction conditions are the same as those in Example 44. The product 3x is isolated as a white solid with a yield of 43%. The structural formula and mass spectrum of the product are as follows:

[0146] HRMS(ESI)C 154 H 246 N 45 O 43 S[M+3H] 3+ Calcd:1148.9395,Found:1148.9369.

[0147] Embodiment 48

[0148] In this embodiment, substrate 2 is N-acetoxybutyramide, and other parameters and reaction conditions are the same as those in Example 47. Product 3y is isolated as a white solid with a yield of 44%. The structural formula and mass spectrum of the product are as follows:

[0149]

[0150] HRMS(ESI)C 151 H 247 N 45 O 43 S[M+2H] 2+ Calcd:1705.9134,Found:1705.9137.

[0151] Embodiment 49

[0152] In this example, substrate 2 is N-acetoxyl oxamide, and other parameters and reaction conditions are the same as in Example 47. The product 3z is isolated as a white solid with a yield of 34%. The structural formula and mass spectrum of the product are as follows:

[0153]

[0154] HRMS(ESI)C 155 H 256 N 45 O 43 S[M+3H] 3+ Calcd:1156.2989,Found:1156.6304.

[0155] Embodiment 50

[0156] Tris(triphenylphosphine)ruthenium dichloride (3 μmol) and benzohydroxamic acid (6 μmol) were fully shaken in 3 mL of methanol for 10 minutes for use. Exenatide (3 μmol), N-acetoxybutyramide (60 μmol), silver acetate (20 μmol), 1 mL of methanol, 1 mL of deionized water, and 0.3 mL of the pre-prepared mixed solution were added to a clean 10 mL reaction tube in sequence and stirred at 37 ° C. 0.3 mL of the pre-prepared mixed solution was added every 30 minutes. After reacting for 2 hours, the product 3aa was purified by semi-preparative liquid chromatography to obtain a white solid with a yield of 17%. The structural formula and mass spectrum of the product are as follows:

[0157]

[0158] HRMS(ESI)C 188 H 292 N 51 O 61 S[M+3H] 3+ Calcd:1424.7029,Found:1424.6992.

[0159] Embodiment 51

[0160] Tris(triphenylphosphine)ruthenium dichloride (1 μmol) and benzohydroxamic acid (2 μmol) were shaken thoroughly in 1 mL of methanol for 10 minutes for later use. c(RGDfM) (10 μmol), fluorescein-N-acetoxy-5-carboxamide (20 μmol), silver acetate (100 μmol), and 2 mL of methanol were added to a clean 10 mL reaction tube in sequence. 1 mL of the above pre-prepared mixture was stirred at 37°C in an air atmosphere for 30 minutes and then purified by semi-preparative liquid chromatography to obtain the product 3ab as a yellow solid with a yield of 53%. The structural formula and mass spectrum of the product are as follows:

[0161]

[0162] HRMS(ESI)C 47 H 50 N 9 O 13 S[M+H] + Calcd:980.3243,Found:980.3003.

[0163] Example 52-54 Cyclic Peptide Synthesis

[0164] Embodiment 52

[0165] The same as Example 1, except that component 1 and component 2 are the same substance Fmoc-L-glutamine (acetyloxy)-methionine methyl ester, the product 3ac is obtained as a white solid with a yield of 75%. The structural formula and mass spectrum data of the product are as follows, and the nuclear magnetic resonance data are shown in Table 2.

[0166]

[0167] HRMS(ESI)C 26 H 30 N 3 O 6 S[M+H] + Calcd:512.1850,Found:512.1849.

[0168] Embodiment 53

[0169] In this embodiment, component 1 and component 2 are the same substance, substance P-5-acetoxy, silver acetate (50 μmol) is added to the reaction system, the solvent is 5 mL methanol, and the other parameters and reaction conditions are the same as those in Example 35. The product 3ad is isolated as a white solid with a yield of 46%. The structural formula and mass spectrum of the product are as follows:

[0170]

[0171] HRMS(ESI)C 63H 97 N 18 O 13 S[M+H] + Calcd:1345.7198,Found:1345.7181.

[0172] Embodiment 54

[0173] In this embodiment, component 1 and component 2 are the same substance, substance P-5-acetoxy, and other parameters and reaction conditions are the same as in Example 53. The product 3ae is isolated as a white solid with a yield of 17%. The structural formula and mass spectrum of the product are as follows:

[0174]

[0175] HRMS(ESI)C 39 H 65 N 10 O 8 S[M+H] + Calcd:833.4702,Found:833.4691.

[0176] Example 55 Peptide Solid Phase Synthesis Modification

[0177] The operation step a of linking the resin to the first amino acid is as follows:

[0178] 0.1 mmol of rink amide MBHA resin was weighed into a 20 mL syringe synthesizer, and then the resin was swollen with dichloromethane (10 mL) for 30 minutes under shaking (300 rpm), then drained and washed with DMF. Then 5 mL of deprotection solution was added, whose composition was DBU:piperidine:DMF (3:3:94, v / v). After stirring for 5 minutes, it was drained, and the deprotection solution was repeatedly added and stirred for another 15 minutes, then drained and washed with DMF (3×10 mL). After draining, a DMF (10 mL) solution containing Fmoc-L-Phe-OH (0.3 mmol), DIPEA (0.6 mmol), HBTU (0.3 mmol) and HOBT (0.3 mmol) was added to the synthesizer, shaken (700 rpm) for 1 hour, and then drained, and then washed with DMF (3×10 mL).

[0179] The deprotection step b is performed as follows:

[0180] 10 mL of deprotection solution was added to the synthesizer, the composition of which was DBU:piperidine:DMF (3:3:94, v / v), stirred for 5 minutes and then drained, the deprotection solution was added again and stirred for 15 minutes, then drained and washed with DMF (3×10 mL).

[0181] The peptide chain extension step c is performed as follows:

[0182] A DMF (10 mL) solution containing Fmoc-amino acid (0.3 mmol), DIPEA (0.6 mmol), HBTU (0.3 mmol) and HOBT (0.3 mmol) was added to the synthesizer. After shaking (700 rpm) for 1 hour, the mixture was dried and washed with DMF (3×10 mL). The last amino acid could be replaced by the corresponding Boc-amino acid.

[0183] The operation of step d of sulfimide modification of polypeptide methionine site is as follows:

[0184] After the peptide sequence extension is completed, it is washed with DCE (3×10 mL), and then N-acetoxybenzamide 2a (0.5 mmol), silver acetate (0.1 mmol), DCE (9 mL), and a fully shaken methanol (1 mL) mixed solution of tris(triphenylphosphine)ruthenium dichloride (0.01 mmol) and benzohydroxamic acid (0.02 mmol) are added in sequence. Shake (700 rpm) to react, add 1 mL of the above methanol mixed solution every 30 minutes, react for 2 hours, and drain, and wash with DCE (3×10 mL) and DMF (3×10 mL) respectively.

[0185] The peptide cleavage and purification process is as follows:

[0186] The resin was washed with dichloromethane (2×10 mL), methanol (1×10 mL), dichloromethane (1×10 mL), and methanol (1×10 mL) in sequence and fully drained. Then, a cutting solution was added and shaken at 300 rpm for 3 hours. The cutting solution composition was TFA / TIPS / H 2 O (9.5mL / 0.25mL / 0.25mL). The cutting liquid was then collected and washed with TFA (3×2mL). The combined cutting liquid was concentrated by vacuum distillation, and then 30mL of ice ether was added. A large amount of solid precipitated. After standing and settling, the wound fluid was separated and extracted with 10mL of deionized water. Repeat the above extraction 2-3 times and combine the aqueous phases. The separated precipitate was dissolved with the above aqueous phase and then freeze-dried. The freeze-dried crude peptide was semi-prepared to obtain the corresponding modified product 3af. The product was a white solid with a total yield of 60% in 12 steps. The mass spectrometry data are as follows:

[0187]

[0188] HRMS(ESI)C 38 H 59 N 8 O 6 S[M+H]+ Calcd:755.4273,Found:755.4262.

[0189] Examples 56-57 Decoupling of sulfilimine polypeptides

[0190] Embodiment 56

[0191] Decoupling of sulfilimine peptide 3t: In a clean 2mL glass bottle, 100μL of aqueous solution of sulfilimine peptide 3t (0.2mM) and 100μL of Bis-Tris buffer solution containing glutathione (2mM) were added in sequence, mixed and allowed to react at 25℃ for 1 hour to generate the corresponding P substance and pentapeptide LKQVY-NH with a conversion rate of more than 99%. 2 The reaction chromatogram is shown in Figure 1 and Figure 2 , the mass spectrum of the product is as follows:

[0192] Substance P: HRMS (ESI) C 63 H 99 N1 8 O 13 S[M+H] + Calcd:1347.7354,Found:1347.7310.

[0193] Pentapeptide (LKQVY-NH 2 ): HRMS(ESI)C 31 H 53 N 8 O 7 S[M+H] + Calcd:649.4032,Found:649.4022.

[0194] Embodiment 57

[0195] Decoupling ring opening of sulfilimine cyclic peptide 3ad: In this example, the polypeptide component is 3ad, and the other parameters and reaction conditions are the same as those in Example 56. The corresponding P substance is generated with a conversion rate of more than 99%. The chromatogram of the reaction is shown in Figure 3 and Figure 4 , the mass spectrum of the product is as follows:

[0196] Substance P: HRMS (ESI) C 63 H 99 N1 8 O 13 S[M+H] + Calcd:1347.7354,Found:1347.7308.

[0197] Table 2 NMR data of the products synthesized in the embodiments of the present invention

[0198]

[0199]

[0200]

[0201] The embodiments described above are only descriptions of the preferred implementation modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should fall within the protection scope determined by the claims of the present invention.

Claims

1. A method for modifying the methionine site of a polypeptide by sulfilimine, characterized in that: In an air atmosphere, a polypeptide containing methionine and N-acyloxyamide are used as raw materials, a ruthenium complex is used as a catalyst, and a reaction is carried out in a solvent in the presence of silver acetate and a ligand. After the reaction is completed, the reaction is separated and purified to obtain a sulfilimine polypeptide 3, and the reaction formula is as follows: In the above reaction formula, the polypeptide component 1 is a polypeptide containing methionine, the sequence length of the polypeptide is 1-39 amino acids, and can be connected to a resin for solid phase reaction; in the N-acyloxyamide component 2, R 1 is a C1-C18 alkyl, phenyl or 5-carboxyfluorescein substituted phenyl, R 2 Any one selected from acetyl, valeryl, benzoyl or 2-chloroacetyl; The ruthenium complex is any one of tris(triphenylphosphine)ruthenium dichloride, benzalbis(tricyclohexylphosphine)ruthenium dichloride or tris(1,10-phenanthroline)ruthenium dichloride.

2. The method for modifying the methionine site of a polypeptide according to claim 1, characterized in that: The solid phase reaction process is: A polypeptide component 1 containing methionine was synthesized on a solid phase resin, and then N-acyloxyamide component 2 (5 equivalents), AgOAc (10 μmol / mL) and DCE (9 mL) were added in sequence, and finally a premix of a ruthenium complex (0.1 equivalent) and a ligand (0.2 equivalent) in methanol (1 mL) was added, and the polypeptide synthesis filter syringe was placed on an oscillator for reaction for 30 minutes (one round of reaction), and then the premixed methanol mixed solution (1 mL) was added again, and the mixture was shaken for reaction for 30 minutes. After a total reaction of 2 hours (four rounds of reaction), the product was cleaved from the resin and purified by semi-preparative high performance liquid chromatography to obtain a purified product.

3. A method for modifying a polypeptide methionine site with sulfilimine as claimed in claim 1 or 2, characterized in that: The molar ratio of the polypeptide component 1, the N-acyloxyamide component 2, the ruthenium complex and the ligand is 1:(1-10):(0.05-0.1):(0.1-0.2), and the amount of silver acetate is 1-50 μmol / mL of the reaction solvent.

4. A method for modifying a polypeptide methionine site with sulfilimine as claimed in claim 1 or 2, characterized in that: The ruthenium complex is tris(triphenylphosphine)ruthenium dichloride.

5. A method for modifying a polypeptide methionine site with sulfilimine as claimed in claim 1 or 2, characterized in that: The ligand is any one of benzohydroxamic acid, benzamide or benzoic acid.

6. A method for modifying a polypeptide methionine site with sulfilimine as claimed in claim 1 or 2, characterized in that: The solvent is any one of methanol, ethanol, acetonitrile, N,N-dimethylformamide, dichloromethane, ethyl acetate, toluene, chloroform, ether, acetone, tetrahydrofuran, 1,4-dioxane or a mixed solution of methanol and water.

7. A method for modifying a polypeptide methionine site with sulfilimine as claimed in claim 1 or 2, characterized in that: The reaction temperature is 0-60°C.

8. The method for modifying the polypeptide methionine site with sulfilimine according to claim 1 or 2, characterized in that: When the polypeptide component 1 and the N-acyloxyamide component 2 are the same substance, the sulfilimine polypeptide 3 is a cyclic peptide.

9. A sulfilimine polypeptide prepared by the method for sulfilimine modification of a polypeptide methionine site as described in claim 1 or 2.

10. Use of the method for modifying the methionine site of a polypeptide according to claim 1 or 2 in the preparation of a polypeptide drug, characterized in that: The sulfilimine polypeptide prepared by the method can undergo N=S bond reduction under the reducing action of glutathione, cysteine ​​or dithiothreitol to achieve polypeptide release, and can be used to prepare polypeptide drugs.